News on Peripheral T-cell lymphoma

SummaryPeripheral T ‑cell lymphomas (PTCL) are a heterogeneous group of rare lymphoid malignancies. Brentuximab vedotin plus cyclophosphamide, doxorubicin, and prednisone (BV+CHP, anti-CD30) is indicated as first-line treatment in the subgroup anaplastic large cell lymphoma (ALCL). Romidepsin plus cyclophosphamide, d oxorubicin, vincristine, and prednisone (Ro-CHOP) is inferior to CHOP in PTCL; however, the subtype angioimmunoblastic T‑cell lymphoma (AITL) might favor Ro-CHOP. An increase of survival after consolidation with autologous stem cell transplantation (ASCT) in first line was found in a retrospective analysis. New antibody (anti-CD47 or anti-KIR3DL2) and CAR T/NK treatments are emerging and entering clinical trials.
Source: Memo - Magazine of European Medical Oncology - Category: Cancer & Oncology Source Type: research